"Iduronate Sulfatase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that specifically cleaves the ester sulfate of iduronic acid. Its deficiency has been demonstrated in Hunter's syndrome, which is characterized by an excess of dermatan sulfate and heparan sulfate. EC 3.1.6.13.
Concept/Terms
Iduronate Sulfatase- Iduronate Sulfatase
- Sulfatase, Iduronate
- Iduronate Sulfate Sulfatase
- Sulfatase, Iduronate Sulfate
- Sulfate Sulfatase, Iduronate
- Sulfoiduronate Sulfatase
- Sulfatase, Sulfoiduronate
- Hunter Corrective Factor
- Corrective Factor, Hunter
- Factor, Hunter Corrective
- Iduronatesulfate Sulfohydrolase
- Sulfohydrolase, Iduronatesulfate
Below are MeSH descriptors whose meaning is more general than "Iduronate Sulfatase".
Below are MeSH descriptors whose meaning is more specific than "Iduronate Sulfatase".
This graph shows the total number of publications written about "Iduronate Sulfatase" by people in Harvard Catalyst Profiles by year, and whether "Iduronate Sulfatase" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
Below are the most recent publications written about "Iduronate Sulfatase" by people in Profiles.
-
An empowered, clinically viable hematopoietic stem cell gene therapy for the treatment of multisystemic mucopolysaccharidosis type II. Mol Ther. 2024 Mar 06; 32(3):619-636.
-
Glial degeneration with oxidative damage drives neuronal demise in MPSII disease. Cell Death Dis. 2016 08 11; 7(8):e2331.
-
Mucopolysaccharidosis type II in a female carrying a heterozygous stop mutation of the iduronate-2-sulfatase gene and showing a skewed X chromosome inactivation. Eur J Med Genet. 2013 Mar; 56(3):159-62.
-
CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS One. 2012; 7(1):e30341.
-
Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011 Nov 07; 6:72.
-
The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr. 2012 Jan; 171(1):181-8.
-
Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010 Jan; 99(1):18-25.
-
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008 Mar; 167(3):267-77.
-
Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl. 2002; 91(439):98-9.
-
Identification of 6 new mutations in the iduronate sulfatase gene. Mutation in brief no. 233. Online. Hum Mutat. 1999; 13(4):338.